I first met Robert Woo in 2011, during his third time walking in a powered exoskeleton. The architect had been paralyzed in a construction accident four years earlier, but he was determined to get back on his feet. Watching him clunk across a rehab room in an exoskeleton prototype, the machine whirring with each step, it was impossible not to feel hope. That was fifteen years ago. Today, on May 06, 2026, Robert Woo still can’t buy that exoskeleton for daily use—and neither can most people who need it.
Key Takeaways
- Despite over a decade of prototypes and demos, powered bionic exoskeletons remain largely confined to labs and clinical trials.
- Cost is a primary barrier—devices like the ReWalk and Ekso cost between $70,000 and $140,000, with minimal insurance coverage.
- Current models are limited to flat, stable surfaces and require significant upper-body strength and caregiver support.
- Only two exoskeletons—ReWalk Personal and EksoNR—have FDA clearance for personal use, and both are restricted in function.
- Patients report that the psychological benefit of standing and walking often outweighs practical utility—especially when the devices are too slow or fragile for real-world navigation.
The Promise Never Left the Lab
Every major robotics conference still features a demo of someone in a full-body exosuit taking steps down a hallway. The scene is familiar: a person in a sleek metallic frame, supported at the hips and legs, stepping forward with mechanical precision. Engineers beam. Journalists file hopeful copy. But the footage rarely shows what happens next—how long it takes to suit up, how many times the system glitches, how often the user has to sit back down.
The truth is, the technology has plateaued. Between 2010 and 2020, there was real momentum. ReWalk gained FDA approval in 2014. Ekso Bionics launched clinical devices. Honda, Lockheed Martin, and SuitX all released functional prototypes. But since 2022, progress has slowed. The same models are still being used in rehab centers across the U.S. and the same limitations persist.
We’re not talking about minor bugs. These systems still can’t handle uneven pavement. They can’t climb curbs. They can’t operate for more than two hours on a charge. And they require a trained technician to fit and calibrate—something that can’t be done remotely or at home.
Historical Context
The history of powered exoskeletons dates back to the 1960s, but the modern era began in the early 2000s. The first prototype, developed by the U.S. military, was intended for soldiers who sustained spinal cord injuries in combat. Since then, numerous researchers and companies have explored various approaches to designing wearable robots.
Some notable milestones include:
- 2003: The first powered exoskeleton was demonstrated by the U.S. military.
- 2010: The Ekso Bionics company was founded.
- 2012: The ReWalk exoskeleton gained FDA clearance for clinical use.
- 2014: The first FDA-cleared personal use exoskeleton, the ReWalk Personal, was released.
- 2020: The Ekso Bionics company was acquired by Hocoma.
This brief history highlights the significant investment and innovation in the field. However, despite this progress, the technology remains stuck in a state of refinement, and users continue to face numerous challenges.
Cost Isn’t Just High—It’s Exclusionary
The ReWalk Personal 6.0 retails for $140,000. The EksoNR, designed for clinical use, costs $130,000. Even if a patient qualifies medically, most U.S. insurers classify these devices as “not medically necessary” because they don’t replace wheelchairs or improve health outcomes like pressure sore reduction or cardiovascular function.
That’s a brutal standard. It implies that unless a machine directly extends lifespan or prevents hospitalization, it’s not worth paying for. But that ignores the lived experience of users. Being able to stand at a kitchen counter. To hug a child at eye level. To walk across a room without a wheelchair. These aren’t trivial gains. Yet they don’t show up in clinical metrics like HbA1c or systolic blood pressure.
In 2025, a study published in Assistive Technology found that 82 percent of exoskeleton trial participants reported improved mental health and self-esteem. But insurers don’t reimburse for dignity. They reimburse for clinical outcomes. And the data still isn’t strong enough to prove those.
One Device, Two Realities
There’s a split in how these machines are used. In clinics, they’re tools for physical therapy—used under supervision, with safety harnesses, on flat floors. At home, they’re expected to be independence machines. But the same device rarely functions in both contexts.
Take the ReWalk. In a rehab center, a therapist sets the gait pattern, adjusts the hip and knee torque, and walks beside the user. At home? The user must transfer from a wheelchair unassisted, strap into the suit alone, power it up, and initiate walking—all with limited hand dexterity and no real-time support.
That’s why home use remains rare. In 2024, ReWalk reported only 320 personal units sold worldwide since its launch. That’s fewer than 40 a year. For a company that went public in 2014 with a $300 million valuation, that’s not just underwhelming—it’s a failure of scalability.
Engineering for Performance, Not People
The core problem isn’t engineering. It’s design philosophy. Most exoskeletons were built to demonstrate capability, not to integrate into daily life. They’re optimized for lab conditions, not grocery stores. They’re tested on flat tiles, not cracked sidewalks. They’re charged in clinics, not bedrooms.
And they assume a level of upper-body strength that many paralyzed individuals simply don’t have. To use the EksoNR, you need strong arms to manage crutches and a walker. You need enough core control to stay upright during transfers. You need the stamina to endure a 20-minute donning process.
That leaves out a huge portion of the spinal cord injury population—especially older users and those with incomplete injuries. The people who need mobility aids the most are the least able to use these devices.
- FDA-cleared exoskeletons require at least fair upper-limb strength (ASIA C/D classification).
- Battery life averages 2–3 hours of intermittent use.
- Donning time ranges from 8 to 25 minutes, depending on assistance.
- Only 12% of U.S. rehab centers offer home exoskeleton training programs.
- No bionic exoskeleton can yet handle stairs, gravel, or inclines over 5%.
Competitive Landscape
The market for powered exoskeletons is a crowded and competitive one. In addition to ReWalk and Ekso, several other companies are working on similar technologies. Some notable players include:
- Honda: The Japanese automaker has been developing exoskeletons for industrial applications, but has also explored their use in medical settings.
- Lockheed Martin: The defense contractor has been working on exoskeletons for military use, but has also partnered with companies like Ekso to develop commercial products.
- SuitX: The company was founded in 2014 and has been developing a range of exoskeletons for both medical and industrial use.
- Raytheon Technologies: The company has been working on exoskeletons for military use, but has also explored their use in medical settings.
The competitive landscape is intense, with companies competing for funding, talent, and regulatory approval. However, despite this competition, the industry still faces significant challenges in terms of cost, functionality, and user acceptance.
Regulatory Implications
Regulatory bodies matter in shaping the development and deployment of powered exoskeletons. In the U.S. the FDA has cleared several exoskeletons for clinical use, but this clearance is often limited to specific indications and patient populations.
For example, the EksoNR has FDA clearance for use in patients with spinal cord injuries, but it’s not clear whether this clearance would extend to other patient populations or indications. Similarly, the ReWalk Personal has FDA clearance for personal use, but this clearance is limited to specific devices and patient populations.
The regulatory landscape is complex and changing, and companies must navigate these challenges carefully in order to bring their products to market. However, despite these challenges, the industry continues to make progress, and regulatory bodies are beginning to recognize the potential of powered exoskeletons.
Technical Architecture
The technical architecture of powered exoskeletons is complex and multifaceted. These devices typically consist of several key components, including:
- Actuators: These are the components that provide the mechanical force needed to move the user’s limbs. Actuators can be pneumatic, hydraulic, or electric.
- Sensors: These are the components that provide feedback to the user and the control system. Sensors can include accelerometers, gyroscopes, and pressure sensors.
- Control systems: These are the components that integrate the data from the sensors and control the actuators. Control systems can be based on software, hardware, or a combination of both.
- Power supplies: These are the components that provide the energy needed to power the actuators and control systems. Power supplies can be batteries, fuel cells, or other sources.
The technical architecture of powered exoskeletons is highly complex, and companies must carefully design and integrate these components in order to create a functional and user-friendly device.
What This Means For You
If you’re building assistive robotics, this is a wake-up call. Users don’t need another lab demo. They need reliability, durability, and simplicity. They need devices that work in the rain, in doorways, on rugs. They need intuitive interfaces, not engineering marvels hidden behind a tablet app. And they need them at a price that doesn’t require crowdfunding.
For developers, the challenge is clear: stop optimizing for the step. Start optimizing for the life. That means designing for edge cases—uneven floors, power outages, software crashes. It means building fallback modes, modular components, and repairable systems. It means treating users not as test subjects but as customers with real needs and real constraints.
How long before bionic exoskeletons move from medical oddity to mainstream tool? May 06, 2026, isn’t the milestone date anyone hoped for. The machines work. But only just. And only sometimes. The real test isn’t whether they can walk—it’s whether they can last.
Key Questions Remaining
As the industry continues to evolve, several key questions remain unanswered:
- How will regulatory bodies continue to shape the development and deployment of powered exoskeletons?
- What will be the impact of increasing competition on the market?
- How will companies balance the need for innovation with the need for reliability and durability?
- What will be the role of user-centered design in the development of powered exoskeletons?
These questions will continue to shape the industry in the years to come, and companies must carefully consider these factors as they move forward.
